Summary: Rhabdoid tumor is a rare, aggressive, and undifferentiated cancer, that can be localized in the central nervous system, in the thorax or in the kidney. 18F-fluorodeoxyglucosepositron emission tomography (FDG-PET) is a noninvasive technique in cancer patients' management. Its role in the diagnosis and staging of rhabdoid renal tumor is not known at all. We report the case of a child with suspected recurrence of rhabdoid renal tumor studied with FDG-PET/computed tomography. A 4-year-old male previously treated for a rhabdoid tumor of the left kidney, underwent PET scan to differentiate local recurrence from postsurgical fibrosis. FDG-PET study showed the presence of intense, multiple, and inhomogeneous tracer uptakes in the left renal fossa (ie, the site of suspected computed tomography recurrence), with the involvement of the adjacent abdominal wall. Further pathologic uptakes were evidenced in the para-aortic, celiac, mesenteric areas, and at the hepatic hilum. Therefore, PET scan allowed a complete disease staging, evidencing unexpected local and distant disease extension. Thus, FDG-PET study could be considered in the evaluation of patients with renal rhabdoid tumor, at least when disease recurrence is suspected.
R
habdoid tumor is a rare, aggressive, and undifferentiated cancer. It can be localized in the central nervous system, in the thorax, or in the kidney. It represents 2% of renal pediatric neoplasms 1 occurring in 80% of cases in children under 2 years of age (1.5:1, male:female). 1, 2 At the histologic evaluation, the appearance of this tumor is similar to a myogenic neoplasm, but it has a different pathogenic origin respect to rhabdomyosarcoma, and also respect to the other pediatric tumors of the kidney (ie, Wilms tumor). Ultra sound and computed tomography (CT) are the essential diagnostic tools. Contrast enhanced CT scan shows the presence of a soft-tissue mass, with some characteristic findings: renal hilum involvement, calcifications, lobular appearance, subcapsular hematoma, vascular invasion, necrosis. 3 At the best of our knowledge, the role of 18F-fluorodeoxyglucose-positron emission tomography/ computed tomography (FDG-PET/CT) in the diagnosis and staging of rhabdoid renal tumor is not known at all. We report the case of a child with suspected recurrence of rhabdoid renal tumor studied with FDG-PET/CT.
CASE PRESENTATION
A 4-year-old male (D.V.) with a rhabdoid tumor of the left kidney, presenting with suspected disease recurrence, came to our PET Center to undergo a whole-body FDG-PET/CT study. Two years ago, in November 2004, D.V. had undergone left nephrectomy and retroperitoneal lymphadenectomy, for an abdominal mass with ultra sound and contrast enhanced CT features highly suspected for a malignant tumor that, at the histopathologic examination, had resulted to be a rhabdoid tumor of kidney, with lymphnodal metastases (stage III disease). Thus, the young patient started a first line adjuvant chemotherapy (AIEOP-TW 2003 D-regime) and local radiation treatment (1950 cGy). In October 2005, local disease recurrence was evidenced by a contrast enhanced CT scan; however, the subsequent second line chemotherapy treatment (Ice and Irinotecan cycles in alternance) was not successful. So, the patient was further treated with third line chemotherapy (VDCy and Ccye cycles in alternance), which allowed reduction of the tumor volume; the residual mass and the spleen were then surgically removed. In May 2006, a new local disease relapse at the left renal fossa was suspected after a contrast enhanced CT study of the abdomen, and an FDG-PET/CT study was required to differentiate local recurrence from postsurgical fibrosis. In June 2006, a whole-body PET/CT scan was performed 60 minutes after the intravenous injection of FDG (90 MBq, 2.5 mCi). At the time of tracer injection, the patient fasted for 10 hours, and the glucose blood level was 75 mg/dL. PET scan showed the presence of intense, multiple, and inhomogeneous tracer uptakes in the left renal fossa (site of the suspected CT recurrence) (Fig. 1) , with involvement of the adjacent abdominal wall (Fig. 2) . Further pathologic tracer uptakes were seen in the para-aortic, celiac, mesenteric areas, and at the hepatic hilum.
CONCLUSIONS
FDG-PET is a noninvasive technique in cancer patients' management. Its usefulness has been proved in the evaluation of some pediatric neoplasms, such as lymphomas, brain tumors, and osteosarcomas, allowing disease staging, differentiation between benign and malignant nature of morphologically undetermined lesions, selection of biopsy site, evaluation of early and final response to treatment, and patient follow-up.
Nowadays, FDG-PET scan is not recommended to study renal tumors, although some interesting findings are reported in the detection of metastases or suspected recurrences. The introduction of the hybrid PET/CT tomograph, that improves the specificity of this technique, could overcome the limitations due to renal excretion of the tracer, encouraging its use in this field.
Some authors suggest a role of PET in the study of uncommon pediatric tumors such as soft-tissue sarcomas, Wilms tumor, neuroblastoma, and rhabdoid tumor of the brain, [4] [5] [6] but nobody reported the use of FDG-PET in rhabdoid renal tumor.
In this case, the tumor showed high uptake values of FDG and PET/CT scan allowed a complete disease staging, evidencing unexpected local and distant disease extension.
So, FDG-PET/CT could be considered in the evaluation of patients with renal rhabdoid tumor, at least when disease recurrence is suspected.
